1. Diagnostic and Prognostic Value of Serum Endocan Levels in Patients With COVID-19
- Author
-
Mehmet T Demir, Murat Güzel, Şener Cindoruk, Emre Özgen, Çetin Kürşad Akpınar, Metin Yadigaroğlu, Murat Yücel, and Selim Görgün
- Subjects
Adult ,Male ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,In patient ,Patient group ,Disease prognosis ,Aged ,Aged, 80 and over ,business.industry ,COVID-19 ,Emergency department ,Middle Aged ,Prognosis ,Neoplasm Proteins ,030220 oncology & carcinogenesis ,Case-Control Studies ,Biomarker (medicine) ,Female ,Proteoglycans ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers - Abstract
We aimed to evaluate whether there was a relationship between endocan (human endothelial cell-specific molecule-1) levels and disease prognosis in patients who presented to the emergency department with coronavirus disease 2019 (COVID-19). A total of 60 patients with COVID-19 who were hospitalized from the emergency department to clinical wards and a control group consisting of healthy adult individuals (n = 28), were included in the study. The majority (93.3%) of the patients were discharged after recovery; 6.7% died. The median endocan value was 243.5 ng/mL in the patient group versus 201.5 ng/mL in the control group ( P = .002). The median endocan level was 240.5 ng/mL in those discharged with recovery and 558 ng/mL in those who died ( P = .001). There was no significant relationship in hospitalization duration, sex, tomography findings, and clinical outcomes. A 202 ng/mL serum endocan level had 86.7% sensitivity and 50% specificity for COVID-19. Serum endocan levels may be a useful biomarker both for the diagnosis of COVID-19 and to predict mortality.
- Published
- 2021